Unicycive granted FDA review for resubmitted marketing application for kidney disease drug
Source: SeekingAlpha
2026-01-29 07:27:59 ET
More on Unicycive Therapeutics
- Seeking Alpha’s Quant Rating on Unicycive Therapeutics
- Historical earnings data for Unicycive Therapeutics
- Financial information for Unicycive Therapeutics
Read the full article on Seeking Alpha
For further details see:
Unicycive granted FDA review for resubmitted marketing application for kidney disease drug
Unicycive Therapeutics Inc.
NASDAQ: UNCY
UNCY Trading
3.3% G/L:
$7.045 Last:
307,194 Volume:
$7.04 Open:
UNCY Latest News
March 06, 2026 11:59:00 am
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm
February 17, 2026 09:15:00 am
Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf
February 04, 2026 07:05:00 am
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit
UNCY Stock Data
$136,900,193
19,189,667
9.45%
14
N/A
Biotechnology & Life Sciences
Healthcare
US
Los Alto
